Wolfe Research analyst Jacob Laclks initiates coverage on Matson (NYSE:MATX) with a Underperform rating and announces Price Target of $80.
7 Analysts Have This to Say About Amylyx Pharma
Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…